Accéder au contenu
Merck

Changes in the cellular fatty acid profile drive the proteasomal degradation of α-synuclein and enhance neuronal survival.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2020-09-16)
Mary Xylaki, Ioanna Boumpoureka, Maroula G Kokotou, Theodoros Marras, Georgia Papadimitriou, Ismini Kloukina, Victoria Magrioti, George Kokotos, Kostas Vekrellis, Evangelia Emmanouilidou
RÉSUMÉ

Parkinson's disease is biochemically characterized by the deposition of aberrant aggregated α-synuclein in the affected neurons. The aggregation properties of α-synuclein greatly depend on its affinity to bind cellular membranes via a dynamic interaction with specific lipid moieties. In particular, α-synuclein can interact with arachidonic acid (AA), a polyunsaturated fatty acid, in a manner that promotes the formation of α-helix enriched assemblies. In a cellular context, AA is released from membrane phospholipids by phospholipase A2 (PLA2 ). To investigate the impact of PLA2 activity on α-synuclein aggregation, we have applied selective PLA2 inhibitors to a SH-SY5Y cellular model where the expression of human wild-type α-synuclein is correlated with a gradual accumulation of soluble oligomers and subsequent cell death. We have found that pharmacological and genetic inhibition of GIVA cPLA2 resulted in a dramatic decrease of intracellular oligomeric and monomeric α-synuclein significantly promoting cell survival. Our data suggest that alterations in the levels of free fatty acids, and especially AA and adrenic acid, promote the formation of α-synuclein conformers which are more susceptible to proteasomal degradation. This mechanism is active only in living cells and is generic since it does not depend on the absolute quantity of α-synuclein, the presence of disease-linked point mutations, the expression system or the type of cells. Our findings indicate that the α-synuclein-fatty acid interaction can be a critical determinant of the conformation and fate of α-synuclein in the cell interior and, as such, cPLA2 inhibitors could serve to alleviate the intracellular, potentially pathological, α-synuclein burden.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
Acide rétinoïque, ≥98% (HPLC), powder
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
Anticorps anti-glycéraldéhyde-3-phosphate déshydrogénase, clone 6C5, clone 6C5, Chemicon®, from mouse
Sigma-Aldrich
Anticorps monoclonal anti-β-actine antibody produced in mouse, clone AC-74, ascites fluid
Sigma-Aldrich
N-Lauroylsarcosine sodium salt, detergent for use in cell lysis
Sigma-Aldrich
Doxycycline hydrochloride
Sigma-Aldrich
Colorant SYBR® Green I pour acides nucléiques sur gel, 10,000 × in DMSO
Sigma-Aldrich
Anticorps de chèvre anti-IgG de lapin, conjugué à de la peroxydase, 1 mg/mL (after reconstitution), Chemicon®
Sigma-Aldrich
Anticorps IgG de chèvre anti-souris (chaînes H+L) conjugué à de la peroxydase, 1 mg/mL (after reconstitution), Chemicon®
Sigma-Aldrich
bisBenzimide H 33258, ≥98% (HPLC and TLC)
Sigma-Aldrich
Ethylhexadecyldimethylammonium bromide, ≥98% (non-aqueous titration)